Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600267'
s PB Ratio Range Over the Past 10 Years
Min: 1.03 Med: 1.72 Max: 2.93
Current: 1.57
During the past 13 years, Zhejiang Hisun Pharmaceutical Co's highest PB Ratio was 2.93. The lowest was 1.03. And the median was 1.72.
SHSE:600267's PB Ratio is ranked better than 57.65% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs SHSE:600267: 1.57
During the past 12 months, Zhejiang Hisun Pharmaceutical Co's average Book Value Per Share Growth Rate was 4.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhejiang Hisun Pharmaceutical Co was 44.20% per year. The lowest was -3.70% per year. And the median was 12.40% per year.
Back to Basics: PB Ratio
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhejiang Hisun Pharmaceutical Co PB Ratio Related Terms
Zhejiang Hisun Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Hisun Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's PB Ratio falls into.
Zhejiang Hisun Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a PB Ratio of 1.57 as of Jul. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. This is near median its historical median of 1.72. Over the past decade, Zhejiang Hisun Pharmaceutical Co's PB Ratio has ranged from 1.03 to 2.93. According to the industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #390 out of 921 companies in the Drug Manufacturers industry, placing it in the top 42.3%.
Is Zhejiang Hisun Pharmaceutical Co's PB Ratio too high?
Zhejiang Hisun Pharmaceutical Co's current PB Ratio of 1.57 is near median its 10-year median of 1.72. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 2.93. The Drug Manufacturers industry median PB Ratio is 1.90. Zhejiang Hisun Pharmaceutical Co's value of 1.57 is 17.4% below this industry median. Based on the distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #390 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #390 out of 921 companies for PB Ratio. This puts Zhejiang Hisun Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 1.90. Zhejiang Hisun Pharmaceutical Co's value of 1.57 is 17.4% below this benchmark. Historically, Zhejiang Hisun Pharmaceutical Co's own PB Ratio has ranged from 1.03 to 2.93 over the past decade. While the company's 10-year median is 1.72 vs. the industry median of 1.90, Zhejiang Hisun Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Hisun Pharmaceutical Co's current PB Ratio of 1.57 is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Hisun Pharmaceutical Co's current PB Ratio is 1.57, which is near median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current PB Ratio is 1.57, which is near median its 10-year median of 1.72 and 17.4% below the Drug Manufacturers industry median of 1.90. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current PB Ratio is 1.57 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
PB Ratio: 1.57 (near median its 10-year median of 1.72)
GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
Industry Position: 17.4% below the Drug Manufacturers median (#390 of 921)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
